藥明康德:強烈反對未經正當程序的預設性且不合理的設定
9月9日,美國眾議院就擬《生物安全法》通過了一項編號為H.R.8333的立法草案。本次通過的立法草案系基於此前美國眾議院監督與問責委員會於 2024年 5月 15日投票所通過的版本作出,其中包括將藥明康德指定為“予以 關注的生物技術公司”,公司強烈反對這種未經正當程序的預設性且不合理的指定。該法案擬限制美國政府提供的資金、貸款或補助被用於在履行政府資助的合同中使用被指定公司提供的某些生物技術設備或服務。儘管有此限制性條款,該法案也包括了一項不溯及既往條款(“祖父”條款),即允許被指定的公司繼續為其客户履行由美國政府資助的合同直至2032年。
在今後數月,擬議《生物安全法》草案還將繼續經歷立法過程。要使擬議的立法草案成為法律,該草案在第 118 屆國會任期屆滿之前還必須獲得美國參議院的批准,並調和與美國眾議院所通過版本之間的任何差異。目前,美國參議院尚未安排對擬議《生物安全法》草案進行審議,其立法進程走向尚不明確。公司將與諮詢顧問協力,繼續與參與立法過程的相關方進行溝通和對話。
從投票結果來看,306票贊成,81票反對,其中民主黨議員反對票79票。值得注意的是,這次投票的贊成率僅為73%,顯著低於眾議院監督委員會歷史上接近98%的平均贊成率。這一顯著差異表明,這次投票在黨派間產生了顯著分歧
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.